earnings

BioNTech's COVID-19 vaccine revenue forecasts lower than expected
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
Biopharma Reporter
BioNTech
earnings
COVID-19
vaccines
Flag link:
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Fierce Pharma
Bayer
earnings
Eylea
Flag link:
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
Fierce Pharma
BeiGene
Brukinsa
earnings
tislelizumab
Flag link:
Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings
Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings
Investors Business Daily
Moderna Therapeutics
earnings
MRNA
vaccines
FDA
cancer vaccines
Flag link:
Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop
Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop
Motley Fool
Pfizer
earnings
vaccines
COVID-19
Flag link:
Medtronic boosts full-year outlook as supply challenges subside
Medtronic boosts full-year outlook as supply challenges subside
Medtech Dive
Medtronic
Medtech
devices
earnings
Flag link:
Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris
Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris
BioSpace
Seagen
earnings
Merck
M&A
Adcetris
Flag link:
Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue
Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue
Endpoints
Biogen
InnoCare Pharma
orelabrutinib
earnings
Flag link:
Lower COVID sales weigh on AZ in fourth quarter
Lower COVID sales weigh on AZ in fourth quarter
Pharmaphorum
AstraZeneca
COVID-19
vaccines
earnings
Flag link:
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints
PharmaLive
Teva Pharmaceutical
earnings
Flag link:
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Fierce Pharma
Sanofi
Dupixent
earnings
Flag link:
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
Endpoints
Regeneron
earnings
Eylea
Flag link:
Oncology, HIV sales lift Gilead’s revenues by 2%
Oncology, HIV sales lift Gilead’s revenues by 2%
Medical Marketing and Media
Gilead Sciences
earnings
HIV
oncology
hepatitis C
Flag link:
Medtech earnings reports: insights from major players' Q4 results
Medtech earnings reports: insights from major players' Q4 results
CP Wire
Medtech
devices
earnings
Edwards Lifesciences
Stryker
Boston Scientific
Siemens Healthineers
Flag link:
Medtech earnings reports: insights from major players' Q4 results
Medtech
devices
earnings
Edwards Lifesciences
Stryker
Boston Scientific
Siemens Healthineers
Flag link:
Q4 earnings roundup: Merck, Lilly, Takeda and BMS release financials
Q4 earnings roundup: Merck, Lilly, Takeda and BMS release financials
Medical Marketing and Media
earnings
Merck
Takeda
Bristol Myers Squibb
Eli Lilly
Flag link:
Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'
Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'
Endpoints
Novo Nordisk
Wegovy
earnings
Flag link:
After a busy year of buildouts, Thermo Fisher sets plans for growth in 2023
After a busy year of buildouts, Thermo Fisher sets plans for growth in 2023
Endpoints
Thermo Fisher
earnings
Flag link:
GSK, after consumer spinoff, touts momentum for core products Cabenuva and Shingrix
GSK, after consumer spinoff, touts momentum for core products Cabenuva and Shingrix
Fierce Pharma
GSK
earnings
spinoff
consumer health
Flag link:
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Yahoo/Benzinga
Novartis
earnings
Sandoz
Flag link:

Pages